Leisure Capital Management Sells 2,921 Shares of Sanofi (NASDAQ:SNY)

Leisure Capital Management lowered its position in Sanofi (NASDAQ:SNY) by 16.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 14,949 shares of the company’s stock after selling 2,921 shares during the quarter. Leisure Capital Management’s holdings in Sanofi were worth $721,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in SNY. Dimensional Fund Advisors LP grew its position in shares of Sanofi by 0.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 318,760 shares of the company’s stock valued at $15,466,000 after buying an additional 1,238 shares during the last quarter. AQR Capital Management LLC acquired a new position in shares of Sanofi in the second quarter worth approximately $344,000. The Manufacturers Life Insurance Company increased its position in Sanofi by 27.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 31,528 shares of the company’s stock valued at $1,530,000 after purchasing an additional 6,756 shares during the period. NewEdge Advisors LLC raised its holdings in Sanofi by 27.2% during the 2nd quarter. NewEdge Advisors LLC now owns 29,587 shares of the company’s stock worth $1,436,000 after purchasing an additional 6,330 shares during the last quarter. Finally, Cetera Investment Advisers lifted its position in shares of Sanofi by 5.5% in the 2nd quarter. Cetera Investment Advisers now owns 188,159 shares of the company’s stock worth $9,130,000 after purchasing an additional 9,810 shares during the period. Institutional investors own 14.04% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. StockNews.com cut shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday. Finally, Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a research note on Thursday. Two equities research analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Sanofi presently has a consensus rating of “Buy” and a consensus target price of $60.00.

Sanofi Stock Performance

Shares of SNY opened at $54.34 on Monday. The stock has a 50-day moving average of $49.24 and a 200-day moving average of $52.30. Sanofi has a one year low of $45.22 and a one year high of $58.97. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 0.74. The company has a market cap of $137.91 billion, a PE ratio of 21.82, a P/E/G ratio of 1.26 and a beta of 0.57.

Sanofi (NASDAQ:SNY) last issued its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.70. Sanofi had a return on equity of 25.58% and a net margin of 12.77%. On average, equities research analysts predict that Sanofi will post 4.34 EPS for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.